Mecanismos moleculares de inflamación durante las agudizaciones de la enfermedad pulmonar obstructiva crónica

Kersul, Ana; Iglesias, Amanda; Ríos, Ángel; Noguera, Aina; Forteza, Aina; Serra, Enrique; Agustí, Àlvar; Cosío, Borja G.

doi:10.1016/j.arbres.2010.12.003

Cited by 54 publications

(24 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This lack of data uniformity may be attributed to different study designs and confounding factors, such as smoking or inhaled corticosteroids (ICS), which are known to influence FeNO levels [20]. Despite the wide range of initial concentrations, most studies report a reduction of FeNO during follow-up [10,12-16,18]. …”

Section: Resultsmentioning

confidence: 99%

“…During recovery, some studies described a reduction of the levels of IL-6, IL-8 and TNFα under bronchodilators and systemic GCS with or without antibiotics [15,55], whereas other studies did not demonstrate a reduction of IL-6 and TNFα levels even 3 months after hospital discharge [16]. The adjunction of theophylline was associated with further reductions in IL-8 and TNFα, suggesting that theophylline may potentially enhance the anti-inflammatory action of standard treatment, notably that of systemic GCS [15].…”

Section: Semi-invasive Samplingmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary biomarkers in COPD exacerbations: a systematic review

Koutsokera¹,

Κostikas²,

Nicod³

et al. 2013

Respir Res

View full text Add to dashboard Cite

Exacerbations of COPD (ECOPD) represent a major burden for patients and health care systems. Innovative sampling techniques have led to the identification of several pulmonary biomarkers. Although some molecules are promising, their usefulness in clinical practice is not yet established. Medline and Highwire databases were used to identify studies evaluating pulmonary sampled biomarkers in ECOPD. We combined 3 terms for ECOPD, 3 for biomarkers and 6 for the sampling method. Seventy-nine studies were considered eligible for inclusion in the review and were analyzed further. Pulmonary biomarkers sampled with non-invasive, semi-invasive and invasive methods were evaluated for their potential to illustrate the disease’s clinical course, to correlate to clinical variables and to predict clinical outcomes, ECOPD etiology and response to treatment. According to published data several pulmonary biomarkers assessed in ECOPD have the potential to illustrate the natural history of disease through the modification of their levels. Among the clinically relevant molecules, those that have been studied the most and appear to be promising are spontaneous and induced sputum biomarkers for reflecting clinical severity and symptomatic recovery, as well as for directing towards an etiological diagnosis. Current evidence on the clinical usefulness of exhaled breath condensate and bronchoalveolar lavage biomarkers in ECOPD is limited. In conclusion, pulmonary biomarkers have the potential to provide information on the mechanisms underlying ECOPD, and several correlate with clinical variables and outcomes. However, on the basis of published evidence, no single molecule is adequately validated for wide clinical use. Clinical trials that incorporate biomarkers in decisional algorithms are required.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Semi-invasive Samplingmentioning

confidence: 99%

Pulmonary biomarkers in COPD exacerbations: a systematic review

Koutsokera¹,

Κostikas²,

Nicod³

et al. 2013

Respir Res

View full text Add to dashboard Cite

show abstract

“…NF-κB, a pivotal transcription factor of the inflammatory response, can be activated by numerous stimuli and participate in the regulation of hundreds of genes by binding to discrete DNA sequences, known as κB elements, in gene promoters and enhancers, such as TGF-β, TNF-α, IL-1β, etc. [21,22]. The expressions of NF-κB in plasma and sputum in COPD patients and smokers with normal lung function increase significantly compare with normal control subjects.…”

Section: Discussionmentioning

confidence: 99%

Long-term effects of three Tiao-Bu Fei-Shen therapies on NF-κB/TGF-β1/smad2 signaling in rats with chronic obstructive pulmonary disease

et al. 2014

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundThe three Tiao-Bu Fei-Shen (Bufei Jianpi, Bufei Yishen, Yiqi Zishen) granules have been confirmed for their beneficial clinical efficacy in chronic obstructive pulmonary disease (COPD) patients on reducing frequency and duration of acute exacerbation, improving syndromes, pulmonary function and exercise capacity. But the short- or long-term mechanism of them is not fully clear. Nuclear factor (NF)-κB/transforming growth factor (TGF)-β1/smad2 signaling pathway is involved in the progress of inflammation and remodeling in chronic obstructive pulmonary disease COPD. This study aimed to explore the long-term effects mechanism of Tiao-Bu Fei-Shen granules by regulating NF-κB/TGF-β/Smads signaling in rats with COPD.MethodsSprague Dawley rats were randomized into control, model, Bufei Jianpi, Bufei Yishen, Yiqi Zishen and aminophylline groups. COPD rats, induced by cigarette smoke and bacterial infections exposures, were administrated intragastricly by normal saline, Bufei Jianpi, Bufei Yishen, Yiqi Zishen granules or aminophylline from week 9 through 20, respectively. At week 20 and 32, lung tissues were harvested. Immunohistochemistry was used to detect interleukin (IL)-1β and tumor necrosis factor (TNF)-α, quantitative real-time polymerase chain reaction (qRT-PCR) was used for TGF-β1 and Smad2 mRNA analysis, western blotting was used to determine the phosphorylation of NF-κB (p-NF-κB) and IκBα (p-IκBα).ResultsCOPD rats had marked airway injury, such as chronic airway inflammation and remodeling, emphysema, which were improved in the three traditional Chinese medicines (TCM)-treated animals. The levels of IL-1β, TNF-α, p-NF-κB, p-IκBα, TGF-β1 and Smad2 were significantly higher in COPD rats than in controls, while they were dramatically reduced in the three TCM- and aminophylline-treated groups. At the meantime, all these endpoints were significantly lower in three TCM-treated groups than in aminophylline group, especially in Bufei Jianpi and Bufei Yishen groups. Compared to week 20, all endpoints decreased significantly in three TCM groups at week 32.ConclusionThe three Tiao-Bu Fei-Shen therapies can reduce pulmonary inflammation and remodeling in COPD and have significant long-term effects. NF-κB/TGF-β1/smad2 signaling might be involved in the mechanism.

show abstract

“…CD 8 + lymphocyte, macrophage and neutrophil levels have been demonstrated to increase in bronchial biopsy tissue, while IL-8, IL-6, tumor necrosis factor-α (TNF-α) and their soluble receptor levels have been demonstrated to increase significantly in the circulation and airducts of patients with COPD in flatland areas, indicating that persistent chronic inflammation is present in COPD (19). Furthermore, IL-8, leukotriene B4 (LTB4) and myeloperoxidase (MPO) levels in the sputum have been revealed to increase markedly in patients with AECOPD in flatland areas (20), as well as increasing in bronchial biopsy tissue and in the blood; however, the IL-10 concentration was observed to decrease significantly (10,11). The results of the present study revealed that the level of IL-8 in the induced sputum was significantly negatively correlated with FEV 1%pred , FEV 1 /FVC and PaO 2 , and was significantly positively correlated with PaCO 2 .…”

Section: Discussionmentioning

confidence: 99%

Expression levels of induced sputum IL-8 and IL-10 and drug intervention effects in patients with acute exacerbated COPD complicated with chronic cor pulmonale at high altitude

Feng

Wan

Yang

et al. 2013

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The aim of this study was to assess the expression levels of induced sputum interleukin (IL)-8 and IL-10 levels in patients with acute exacerbated chronic obstructive pulmonary disease (AECOPD) complicated with chronic cor pulmonale (CCP) at high altitude, and to evaluate the intervention effects of an inhaled corticosteroid (ICS) and a β2-adrenoceptor agonist in this disease. A total of 186 patients with AECOPD complicated with CCP were randomly divided into three groups, with 62 cases in each. With regard to the two treatment groups, group A was treated with salmeterol/fluticasone (50 μg/250 μg, respectively) by airway inhalation twice daily, while group B received budesonide (1 mg) as a spray inhalation, twice daily. The routine treatment group (group C) received only routine treatment. The levels of IL-8 and IL-10 in the induced sputum and the predicted percentage of forced expiratory volume in one second (FEV1%pred), partial pressure of oxygen in arterial blood (PaO2) and partial pressure of carbon dioxide in arterial blood (PaCO2) were examined on admission and at a stable stage two weeks following treatment. Forty healthy volunteers served as a control group (group D). Compared with group D values, the IL-8 induced sputum level and the PaCO2 were significantly increased, while the level of IL-10, FEV1%pred and the PaO2 were markedly decreased in the three COPD groups prior to treatment. Following treatment, the induced sputum IL-8 level and the PaCO2 were significantly decreased, while the induced sputum IL-10 level, FEV1%pred and the PaO2 were markedly increased in the three treatment groups compared with the values pre-therapy (all P<0.01). The post-treatment parameters were significantly different among the three groups (P<0.01). The results indicate that IL-8 and IL-10 are involved in the airway inflammation of AECOPD complicated by CCP. Treatment with an ICS was demonstrated to be a successful method of reducing the local expression of IL-8 and increasing the local expression of IL-10; however, ICS combined with a long-acting β2-adrenoceptor agonist (LABA) was more effective than the sole administration of ICS in patients with AECOPD complicated by CCP at high altitude.

show abstract

Mecanismos moleculares de inflamación durante las agudizaciones de la enfermedad pulmonar obstructiva crónica

Cited by 54 publications

References 32 publications

Pulmonary biomarkers in COPD exacerbations: a systematic review

Pulmonary biomarkers in COPD exacerbations: a systematic review

Long-term effects of three Tiao-Bu Fei-Shen therapies on NF-κB/TGF-β1/smad2 signaling in rats with chronic obstructive pulmonary disease

Expression levels of induced sputum IL-8 and IL-10 and drug intervention effects in patients with acute exacerbated COPD complicated with chronic cor pulmonale at high altitude

Contact Info

Product

Resources

About